94 Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC)

• Heather McArthur,
• William Redmond,
• Walter Urba,
• Yoshinobu Koguchi,
• Valerie Conrad,
• David Page,
• Nathan Polaske,
• Alison Conlin,
• Venkatesh Rajamanickam,
• Brady Bernard,
• Isaac Kim,
• Brie Chun,
• Joanna Pucilowska,
• Shu Ching Chang,
• Benjamin Nikitin,
• Paul Fields,
• Mark Schmidt

Affiliations

Heather McArthur

Aff1 grid.51462.340000000121719952Memorial Sloan Kettering Cancer Center New York NY USA

William Redmond

1Earle A. Chiles Research Institute, Portland, OR, USA

Walter Urba

1Providence Cancer Institute, Portland, OR, USA

Yoshinobu Koguchi

1Providence Cancer Institute, Portland, OR, USA

Valerie Conrad

Aff283 grid.415337.7Earle A. Chiles Research Institute, Providence Cancer Center Portland OR USA

David Page

Aff319 grid.240531.1000000040456863XEarle A. Chiles Research Institute, Providence Portland Medical Center Portland OR USA

Nathan Polaske

Aff324 grid.418158.10000000405344718Ventana Medical Systems, Inc. Tucson AZ USA

Alison Conlin

Aff537 grid.240531.1000000040456863XProvidence Portland Medical Center Portland OR USA

Venkatesh Rajamanickam

Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA

Brady Bernard

Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA

Isaac Kim

3EACRI, Providence Cancer Center, Portland, OR, USA

Brie Chun

1EACRI, Providence Cancer Institute, Portland, OR, USA

Joanna Pucilowska

1EACRI, Providence Cancer Institute, Portland, OR, USA

Shu Ching Chang

2Providence St. Joseph Health, Portland, OR, USA

Benjamin Nikitin

1EACRI, Providence Cancer Institute, Portland, OR, USA

Paul Fields

4Adaptive Biotechnologies, Seattle, WA, USA

Mark Schmidt

1EACRI, Providence Cancer Institute, Portland, OR, USA